• Sign In
  • My Marketwire Account
  • Marketwire Resonate
  • News Dashboard 2.0
  • Mediahub
  • Personal Beat
  • Hot Off the Wire
• Register
• Français
• Marketwired Blog
• Careers
• Contact Marketwired

Browse By:

• Industry
  • Aerospace and Defense
  • Agriculture
  • Automotive
  • Chemicals
  • Computers and Software
  • Education and Training
  • Electronics and Semiconductors
  • Energy and Utilities
  • Environment
  • Financial Services
  • Food and Beverage
  • Government
  • Lifestyle and Leisure
  • Manufacturing and Production
  • Media and Entertainment
  • Medical and Healthcare
  • Pharmaceuticals and Biotech
  • Professional Services
  • Real Estate and Construction
  • Retail
  • Sports
  • Telecom
  • Transportation and Logistics
  • Travel and Hospitality
• Topic
  • Associations
  • Bankruptcy
  • Class action
  • Conference calls
  • Dividends
  • Earnings
  • Earnings projections
  • Financing agreements
  • Initial public offerings
  • Investment opinion
  • Management changes
  • Media advisory
  • Mergers and acquisitions
  • Special news events
  • Stock splits
  • Stock/other market news
  • Trade shows
  • Webcasts
• Type
  • News Releases
  • Media Advisories
  • Feature Packs
  • Webcasts
  • Social Media 2.0

News Room: Trials

Invivoscribe Prevails in German District Court (FLT3 Patent Infringement Action)
SAN DIEGO, CA--(Marketwired - May 14, 2013) - MLL Münchner Leukämielabor GmbH ("MLL") Laboratories has been found guilty of patent infringement in a matter involving FLT3 testing patent rights...(more)
Invivoscribe Technologies, Inc.  
May 14, 2013 00:01 ET
 

 

Invivoscribe siegt in Deutschem Landesgericht (FLT3 Patentverletzungsverfahren)
SAN DIEGO, CA--(Marketwired - May 14, 2013) - Die MLL Münchner Leukämielabor GmbH ("MLL") Laboratorien wurden der Verletzung von Patentrechten bezüglich FLT3 Mutationstests, für welche...(more)
Invivoscribe Technologies, Inc.  
May 14, 2013 00:01 ET
 

 

La Jolla Pharmaceutical Company Announces First-Quarter 2013 Financial Results and Highlights Recent Corporate Progress
SAN DIEGO, CA--(Marketwired - May 13, 2013) -  La Jolla Pharmaceutical Company (OTCBB: LJPC) (the "Company" or "La Jolla"), a leader in the development of therapeutics targeting galectin proteins...(more)
La Jolla Pharmaceutical Company  
May 13, 2013 16:52 ET
 

 

Medivation Names Stephen Kelsey Senior Vice President of New Projects
SAN FRANCISCO, CA--(Marketwired - May 13, 2013) - Medivation, Inc. (NASDAQ: MDVN) today announced that Stephen M. Kelsey, M.D., F.R.C.P., F.R.C.Path. will join Medivation in the newly-created...(more)
Medivation  
May 13, 2013 16:10 ET
 

 

Frost & Sullivan Honors Selventa With 2013 Technology Leadership Award for "Systems Diagnostics"
CAMBRIDGE, MA--(Marketwired - May 13, 2013) - Selventa today announced that Frost & Sullivan has named Selventa as the winner of its 2013 Technology Leadership Award for the company's Systems...(more)
Selventa  
May 13, 2013 09:50 ET
 

 

Patent Litigation Settlement and License Between EMD Millipore Corporation and W. L. Gore & Associates, Inc.
ELKTON, MD--(Marketwired - May 13, 2013) - EMD Millipore Corporation and W. L. Gore & Associates, Inc. announced today the settlement of patent infringement disputes between Millipore and Gore...(more)
W. L. Gore & Associates  
May 13, 2013 09:00 ET
 

 

Nuvilex, Inc.'s Dr. Gerald Crabtree Discusses Upcoming Phase III Cancer Trials, Fast Track and Orphan Drug Status
NEW YORK, NY--(Marketwired - May 13, 2013) - Nuvilex, Inc. (OTCQB: NVLX) COO Dr. Gerald Crabtree is no stranger to late stage clinical trials or dealing with blockbuster therapies for cancer...(more)
Nuvilex, Inc.  
May 13, 2013 08:30 ET
 

 

Marina Biotech Announces That Licensee Mirna Therapeutics Reported Initiation of a Phase 1 Clinical Trial of Anticancer Drug MRX34
BOTHELL, WA--(Marketwired - May 13, 2013) -   Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that the Company's...(more)
Marina Biotech, Inc.  
May 13, 2013 08:00 ET
 

 

Federman & Sherwood Announces That a Securities Class Action Lawsuit Has Been Filed Against Ventrus Bioscences, Inc. (NASDAQ: VTUS)
OKLAHOMA CITY, OK--(Marketwired - May 12, 2013) - On May 9, 2013, a class action lawsuit was filed in the United States District Court for the Southern District of New York against Ventrus...(more)
Federman & Sherwood  
May 12, 2013 00:16 ET